Literature DB >> 20190473

Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C.

Masanori Yamazaki1, Ai Sato, Teiji Takeda, Mitsuhisa Komatsu.   

Abstract

We report two cases of type 1 diabetes mellitus (T1DM) which developed after interferon (IFN) therapy for chronic hepatitis C. The patients had experienced abrupt hyperglycemia with positive anti-glutamic acid decarboxylase antibodies, resulting in initiation of insulin therapy. In one case, insulin therapy could be discontinued because endogenous insulin secretion was preserved at the onset and pancreatic beta cell function was recovered thereafter. In the other case with Hashimoto's thyroiditis and Sjögren's syndrome, continuation of insulin therapy was necessary because blood glucose levels were unstably controlled. Lasting autoimmunity superior to immunosuppressive mechanism may be associated with distinct clinical courses in these cases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190473     DOI: 10.2169/internalmedicine.49.2656

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  13 in total

Review 1.  Constitutive type I interferon modulates homeostatic balance through tonic signaling.

Authors:  Daniel J Gough; Nicole L Messina; Christopher J P Clarke; Ricky W Johnstone; David E Levy
Journal:  Immunity       Date:  2012-02-24       Impact factor: 31.745

2.  p204-Mediated innate antiviral responses in mouse adipose cells and their effects on cell functions.

Authors:  Lili Yu; Peng Liu; Zhenghui Liu; Weiwei Zhu; Keqin Yan; Qiaoyuan Chen; Daishu Han
Journal:  Immunol Cell Biol       Date:  2014-10-07       Impact factor: 5.126

Review 3.  Hepatitis C virus infection and type 1 and type 2 diabetes mellitus.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Dilia Giuggioli; Andrea Di Domenicantonio; Ilaria Ruffilli; Alda Corrado; Silvia Fabiani; Santino Marchi; Clodoveo Ferri; Ele Ferrannini; Poupak Fallahi
Journal:  World J Diabetes       Date:  2014-10-15

Review 4.  Drug-Induced Hyperglycaemia and Diabetes.

Authors:  Neila Fathallah; Raoudha Slim; Sofien Larif; Houssem Hmouda; Chaker Ben Salem
Journal:  Drug Saf       Date:  2015-12       Impact factor: 5.606

5.  Eosinophilic gastroenteritis in a patient with chronic hepatitis C who received treatment with pegylated interferon.

Authors:  Genryu Hirano; Atsushi Fukunaga; Tetsuro Sohda; Hideo Kunimoto; Kaoru Yotsumoto; Kunitoshi Sakurai; Hideyuki Iwashita; Shuichi Ueda; Keiji Yokoyama; Daisuke Morihara; Yoshitaka Tomioka; Akira Anan; Masashi Yamaguchi; Yasuaki Takeyama; Kouichi Eguchi; Masaharu Sakamoto; Makoto Irie; Kaoru Iwata; Satoshi Shakado; Kunihiko Aoyagi; Shotaro Sakisaka
Journal:  Clin J Gastroenterol       Date:  2012-02-24

Review 6.  Interferon therapy in hepatitis C leading to chronic type 1 diabetes.

Authors:  Taiba Zornitzki; Stephen Malnick; Lyudmila Lysyy; Hilla Knobler
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 7.  Type I interferon in organ-targeted autoimmune and inflammatory diseases.

Authors:  Mary K Crow
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

8.  The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison's disease.

Authors:  A Hellesen; K Edvardsen; L Breivik; E S Husebye; E Bratland
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

9.  Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review.

Authors:  Reiko Oka; Naoki Hiroi; Rika Shigemitsu; Mariko Sue; Yasuo Oshima; Mayumi Yoshida-Hiroi
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2011-08-23

10.  Clinical and genetic characteristics of patients with type 1 diabetes associated with interferon therapy.

Authors:  Koji Nakanishi; Satoshi Saitoh
Journal:  Diabetes Care       Date:  2011-02       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.